



## AllerGen NCE Inc.

AllerGen was selected for NCE support in 2004 and launched its research program in April 2005.

### ***AllerGen's Mission:***

AllerGen's mission is to catalyze and support discovery, development, networking, capacity building, commercialization and knowledge translation that contribute to reducing the morbidity, mortality and socio-economic burden of allergic and related immune diseases.

### ***AllerGen's Vision:***

AllerGen's vision is to create an enduring network of allergy and immune disease experts whose discovery and development efforts contribute to reducing the impact of allergic and related immune diseases nationally and globally.

### ***AllerGen's Strategic Goals are to:***

- Catalyze and support innovative research that contributes to the **discovery** of the causes of, and ways to prevent, control or eliminate allergic and related immune diseases.
- Catalyze and facilitate the **development** of new research platforms, tools, processes, products and services arising from discoveries, and promote their commercialization, their use and their influence on public policy.
- Develop and maintain **networking** and **partnership** arrangements that enable knowledge and technology exchange and exploitation (KTEE) and reposition Canada at the forefront of innovation.
- Create new opportunities for the **training** of highly qualified personnel in allergy research, patient care, innovation and the health system, and advance professional and lay knowledge about allergic and related immune diseases.
- Provide responsible, cost effective and accountable **management**, administration and support to all aspects of AllerGen's activities.

From 2009 to 2012, AllerGen seeks to invest in nationally networked research teams demonstrating excellence, productivity and offering unique capacity building opportunities, as well as in research that builds on and extends existing AllerGen and partner investments with potential to accelerate social and economic impact through application of research results to real world problems and challenges faced by partner organisations, sectors of the Canadian economy and/or society.

AllerGen research priorities include three research foci of strategic importance to the generation of new knowledge with potential for social and economic impact in the area of allergic and related immune disease.

## **1. Programme A** – Gene-Environment Interactions

Strategic Focus: Genetics, environmental exposures, and gene-environment interactions in allergy and asthma

## **2. Programme B** – *Diagnostics and Therapeutics*

Strategic Focus: Biomarkers, immune monitoring and drug development/discovery

## **3. Programme C** – *Public Health, Ethics, Policy and Society*

Strategic Focus: Allergic disease management and surveillance

In addition, four cross-programmatic, multidisciplinary research thrusts fostered by AllerGen since 2005 are continuing research investment priorities for 2009-2012.

### ***Cross-programmatic Research teams in priority areas:***

#### ***Established Cross-programmatic Teams***

4. *The Canadian Healthy Infant Longitudinal Development (CHILD) Study*

5. *Food Allergy and Anaphylaxis*

#### ***Emerging Cross-programmatic Teams***

6. *Mind-Body Interactions and Allergic Disease*

7. *Occupational and Work-related Allergy and Asthma*

AllerGen NCE Inc.  
Michael DeGroote Centre for Learning and Discovery,  
Room 3120, McMaster University  
1200 Main Street West  
Hamilton, ON L8N 3Z5  
Tel. 905.525.9140 ext.26502  
Fax. 905.524.0611  
[www.allergen-nce.ca](http://www.allergen-nce.ca)

**Canada**

AllerGen is supported by the Government of Canada through the Networks of Centres of Excellence program. AllerGen est appuyé par le gouvernement du Canada dans le cadre d'un programme des Réseaux de centres d'excellence.